Parkinson’s disease (PD) is a degenerative, chronic and irreversible condition. Palliative medicine may play an important role in the care of patients with PD to maintain the quality of life. Scopolamine is a non-competitive antagonist at muscarinic acetylcholine receptors, which was used many years ago in the treatment for PD. To the best of our knowledge, there are no previously reported cases of the use of scopolamine for symptom relief at the end of life in patients with PD. The case reported here shows that treatment with a subcutaneous scopolamine was a useful alternative in a terminal cancer patient with severe tremors unable to take oral PD medication.
National Institute for Health and Clinical Excellence. Parkinson’s Disease: Diagnosis and Management in Primary and Secondary Care. London: National Institute for Health and Clinical Excellence, 2006.
2.
HudsonPLToyeCKristjansonLJ. Would people with Parkinson's disease benefit from palliative care?Palliat Med2006; 20: 87–94.
PoeweW. Treatments for Parkinson disease past achievements and current clinical needs. Neurology2009; 72(Suppl. 2): S65–S73.
5.
BrocksDR. Anticholinergic drugs used in Parkinson's disease: an overlooked class of drugs from a pharmacokinetic perspective. Pharm Pharmaceut Sci1999; 2: 39–46.
6.
DeleuDHanssensYNorthwayMG. Subcutaneous apomorphine: an evidence based review of its use in Parkinson’s disease. Drugs Aging2004; 21: 687–709.
7.
TyneHLParsonsJSinnottAFoxSFletcherNSteigerMJ. A 10 year retrospective audit of long term apomorphine use in Parkinson’s disease. J Neurol2004; 251: 1370–1374.
8.
DewhurstFLeeMWoodB. The pragmatic use of apomorphine at the end of life. Palliat Med2009; 23: 777–779.
9.
SepúlvedaCMarlinAYoshidaTUllrichA. Palliative care: the World Health Organization’s global perspective. J Pain Symptom Manage2002; 24: 91–96.
